Naomi Abe, MD

Associate Clinical Professor of Pediatric Emergency Medicine

Location: UCSF San Francisco & Oakland

Specialty: Pediatric Emergency Medicine

Publications

A Japanese boy with apparent Bohring-Opitz or "C-like" syndrome.

Osaki M, Makita Y, Miura J, Abe N, Noguchi S, Miyamoto A

TAS0612, a Novel RSK, AKT, and S6K Inhibitor, Exhibits Antitumor Effects in Preclinical Tumor Models.

Ichikawa K, Ito S, Kato E, Abe N, Machida T, Iwasaki J, Tanaka G, Araki H, Wakayama K, Jona H, Sugimoto T, Miyadera K, Ohkubo S

Maternal Mental Health Diagnoses and Infant Emergency Department Use, Hospitalizations, and Death.

Abe N, Baer RJ, Jelliffe-Pawlowski L, Chambers CD, Bandoli G

[Posterior reversible encephalopathy syndrome during nilotinib treatment for chronic myeloid leukemia].

Kudo D, Suzuki H, Abe N, Hirai R, Tanimura A, Takeshita M, Miwa A

Predictive Factors for Delayed Surgical Intervention in Children With Epidural Hematomas.

Abe N, Gardiner M, Dory C, Gonda D, Harvey H, Hilfiker M, Hollenbach K, Kanegaye JT

TAS6417/CLN-081 Is a Pan-Mutation-Selective EGFR Tyrosine Kinase Inhibitor with a Broad Spectrum of Preclinical Activity against Clinically Relevant EGFR Mutations.

Udagawa H, Hasako S, Ohashi A, Fujioka R, Hakozaki Y, Shibuya M, Abe N, Komori T, Haruma T, Terasaka M, Fujita R, Hashimoto A, Funabashi K, Yasuda H, Miyadera K, Goto K, Costa DB, Kobayashi SS

Dietary iron restriction leads to a reduction in hepatic fibrosis in a rat model of non-alcoholic steatohepatitis.

Abe N, Tsuchida T, Yasuda SI, Oka K

Longitudinal characterization of diet-induced genetic murine models of non-alcoholic steatohepatitis with metabolic, histological, and transcriptomic hallmarks of human patients.

Abe N, Kato S, Tsuchida T, Sugimoto K, Saito R, Verschuren L, Kleemann R, Oka K

TAS6417, A Novel EGFR Inhibitor Targeting Exon 20 Insertion Mutations.

Hasako S, Terasaka M, Abe N, Uno T, Ohsawa H, Hashimoto A, Fujita R, Tanaka K, Okayama T, Wadhwa R, Miyadera K, Aoyagi Y, Yonekura K, Matsuo K

The p53 activator overcomes resistance to ALK inhibitors by regulating p53-target selectivity in ALK-driven neuroblastomas.

Miyazaki M, Otomo R, Matsushima-Hibiya Y, Suzuki H, Nakajima A, Abe N, Tomiyama A, Ichimura K, Matsuda K, Watanabe T, Ochiya T, Nakagama H, Sakai R, Enari M